Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin

References

• Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94.
   PubMed Web of Science ®Google Scholar
• Rossi C, Chrétien ML, Casasnovas RO. Antibody-drug conjugates for the treatment of hematological malignancies: a comprehensive review. Target Oncol. 2018;13(3):287–308.
   PubMed Web of Science ®Google Scholar
• Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804.
   PubMed Web of Science ®Google Scholar
• Duerr C, Friess W. Antibody-drug conjugates- stability and formulation. Eur J Pharm Biopharm. 2019;139:168–176.
   PubMed Web of Science ®Google Scholar
• Chalouni C, Doll S. Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res. 2018;37(1):20.
   PubMedGoogle Scholar
• Shingleton JR, Dave SS. Polatuzumab vedotin: honing in on relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):166–168.
   PubMed Web of Science ®Google Scholar
• Vezina HE, Cotreau M, Han TH, et al. Antibody-drug conjugates as cancer therapeutics: past, present, and future. J Clin Pharmacol. 2017;57(Suppl 10):S11–S25.
   PubMed Web of Science ®Google Scholar
• Frigerio M, Kyle AF. The chemical design and synthesis of linkers used in antibody drug conjugates. Curr Top Med Chem. 2017;17(32):3393–3424.
   PubMed Web of Science ®Google Scholar
• Wolska-Washer A, Robak T. Safety and tolerability of antibody-drug conjugates in cancer. Drug Saf. 2019;42(2):295–314.
   PubMed Web of Science ®Google Scholar
• Lambert JM, Berkenblit A. Antibody-drug conjugates for cancer treatment. Annu Rev Med. 2018;69:191–207.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Molina A. Investigational antibody-drug conjugates for treatment of B-lineage malignancies. Clin Lymphoma Myeloma Leuk. 2018;18(7):452–468.e4.
   PubMed Web of Science ®Google Scholar
• Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549–559.
   PubMed Web of Science ®Google Scholar
• Pagano L, Fianchi L, Caira M, et al. The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26(25):3679–3690.
   PubMed Web of Science ®Google Scholar
• Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24.
   PubMed Web of Science ®Google Scholar
• ADCENTRIS PI 2019. [cited 2020 Jan 16]. Available from: https://www.seattlegenetics.com/application/files/1915/2157/0234/adcentris_USPI.pdf.
   Google Scholar
• BESPONSA PI 2019. [cited 2020 Jan 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf
   Google Scholar
• Aujla A, Aujla R, Liu D. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019;7:9. .
   PubMed Web of Science ®Google Scholar
• LUMOXITI PI 2019. [cited 2020 Jan 16]. Available from: https://www.azpicentral.com/lumoxiti/lumoxiti.pdf.
   Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715.
   PubMed Web of Science ®Google Scholar
• POLIVY PI 2019. [cited 2020 Jan 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf
   Google Scholar
• de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14–23.
   PubMed Web of Science ®Google Scholar
• Maruani A. Bispecifics and antibody-drug conjugates: a positive synergy. Drug Discov Today Technol. 2018;30:55–61.
   PubMedGoogle Scholar
• García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res. 2018;78(9):2159–2165.
   PubMed Web of Science ®Google Scholar
• Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358–2364.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res. 2006;30(Suppl 1):S16–21.
   PubMed Web of Science ®Google Scholar
• Gong Q, Hazen M, Marshall B, et al. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation. MAbs. 2016;8(6):1098–1106.
   PubMed Web of Science ®Google Scholar
• Uy N, Nadeau M, Stahl M, et al. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. J Blood Med. 2018;9:67–74.
   PubMed Web of Science ®Google Scholar
• Troussard X, Cornet E. Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2017;92(12):1382–1390.
   PubMed Web of Science ®Google Scholar
• Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616–623.
   PubMed Web of Science ®Google Scholar
• He X, Kläsener K, Iype JM, et al. Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells. Embo J. 2018;37(11):e97980.
   PubMed Web of Science ®Google Scholar
• Cabezudo E, Carrara P, Morilla R, et al. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica. 1999;84(5):413–418.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol. 2000;64(4):275–281.
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Stewart CC, Donohue K, et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93–114.
   PubMed Web of Science ®Google Scholar
• Abdel-Ghafar AA, El Din El Telbany MA, Mahmoud HM, et al. Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry. Hematol Rep. 2012;4(1):e3.
   PubMedGoogle Scholar
• Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2011;20(1):75–85.
   PubMed Web of Science ®Google Scholar
• Fuh FK, Looney C, Li D, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174(8):628–640.
   PubMed Web of Science ®Google Scholar
• Nagayama A, Ellisen LW, Chabner B, et al. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12(6):719–739.
   PubMed Web of Science ®Google Scholar
• Bargh JD, Isidro-Llobet A, Parker JS, et al. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48(16):4361–4374.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628.
   PubMed Web of Science ®Google Scholar
• Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736–1742.
   PubMed Web of Science ®Google Scholar
• Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem. 1990;265(28):17141–17149.
   PubMed Web of Science ®Google Scholar
• Pettit GR. The dolastatins. Fortschr Chem Org Naturst. 1997;70:1–79.
   PubMedGoogle Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–784.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
   PubMed Web of Science ®Google Scholar
• Beckwith M, Urba WJ, Longo DL. Growth inhibition of human lymphoma cell lines by the marine products, Dolastatins 10 and 15. J Natl Cancer Inst. 1993;85(6):483–488.
   PubMedGoogle Scholar
• Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–2729.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78(16):1763–1767.
   PubMed Web of Science ®Google Scholar
• Ma H, Sawas A. Combining biology and chemistry for a new take on chemotherapy: antibody-drug conjugates in hematologic malignancies. Curr Hematol Malig Rep. 2018;13(6):555–569.
   PubMed Web of Science ®Google Scholar
• Polatuzumab vedotin Drug Description. J Antibody-Drug Conjugates. [cited 2020 Mar 19]. Available from: https://www.adcreview.com/polatuzumab-vedotin-drug-description/
   Google Scholar
• Gemtuzumab ozogamicin Drug Description. J Antibody-Drug Conjugates. [cited 2020 Mar 19]. Available from: https://www.adcreview.com/gemtuzumab-ozogamicin-mylotarg/
   Google Scholar
• Brentuximab vedotin Drug Description. J Antibody-Drug Conjugates. [cited 2020 Mar 19]. Available from: https://www.adcreview.com/brentuximab-vedotin-sgn35/
   Google Scholar
• Goldmacher VS, Kovtun YV. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv. 2011;2(3):39–416.
   Google Scholar
• Herrera AF, Patel M, Burke JM, et al. A phase I study of the Anti-CD79b THIOMAB™ antibody drug conjugate DCDS0780A in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Blood. 2017;130(Suppl 1):4129.
   Google Scholar
• Crump M. Management of relapsed diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1195–1213.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–125.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60(6):393–408.
   PubMed Web of Science ®Google Scholar
• Advani RH, Lebovic D, Chen A, et al. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23(5):1167–1176.
   PubMed Web of Science ®Google Scholar
• Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate Inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–583.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al., Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165. .
   PubMed Web of Science ®Google Scholar
• Sehn LH, Matasar MJ, Flowers CR, et al. Polatuzumab vedotin plus bendamustine with rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a Phase Ib/II randomized study. Poster presented at the 61st ASH Annual Meeting & Exposition; December 7–10, 2019; Orlando, Florida, USA. Abstract 4081.
   Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019a;20(7):998–1010.
   PubMed Web of Science ®Google Scholar
• Tilly H, Flowers C, Friedberg JW, et al., POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. J Clin Oncol. 2019b;37(15 Suppl):TPS7571.
   Web of Science ®Google Scholar
• Phillips T, Brunvand M, Chen AI, et al. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory B-cell Non-Hodgkin lymphoma: a phase Ib/II study. Manuscript in preparation.
   Google Scholar
• POLIVY EPAR Medicine overview 2020. [cited 2020 Mar 25]. Available from: https://www.ema.europa.eu/en/documents/overview/polivy-epar-medicine-overview_en.pdf
   Google Scholar
• Mukherjee A, Waters AK, Babic I, et al. Antibody drug conjugates: progress, pitfalls, and promises. Hum Antibodies. 2019;27(1):53–62.
   PubMedGoogle Scholar
• Lyon R. Drawing lessons from the clinical development of antibody-drug conjugates. Drug Discov Today Technol. 2018;30:105–109.
   PubMedGoogle Scholar